Elecoglipron and dapagliflozin together for adults with type 2 diabetes
Tests elecoglipron with dapagliflozin, versus each alone, in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Albuquerque, Annapolis, Atlanta, Bakersfield, Beachwood, Boston, Brooklyn, Chicago, Dallas, Elkhorn, Evansville, Huntsville, Kingsport, Kingwood, Lake City, Lakeland, Layton, Little Rock, Los Angeles, Lutherville-Timonium, Maumee, McKinney, Mobile, Nashville, Newport News, Norman, Ontario, Oxon Hill, Paris, Philadelphia, Raleigh, Redmond, Ridgeland, Rosedale, San Antonio, Sheffield, Sioux City, Skokie, South Jordan, Toms River, Troy, Vienna, Webster, and Zachary, United StatesSee the 44 sites
- Phase
- Phase 3
Where in United States
- AlbuquerqueAlbuquerque, United StatesTaking people
- AnnapolisAnnapolis, United StatesNot yet recruiting
- AtlantaAtlanta, United StatesNot yet recruiting
- BakersfieldBakersfield, United StatesNot yet recruiting
- BeachwoodBeachwood, United StatesNot yet recruiting
- BostonBoston, United StatesNot yet recruiting
- BrooklynBrooklyn, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- DallasDallas, United StatesTaking people
- ElkhornElkhorn, United StatesNot yet recruiting
- EvansvilleEvansville, United StatesNot yet recruiting
- HuntsvilleHuntsville, United StatesNot yet recruiting
- KingsportKingsport, United StatesTaking people
- KingwoodKingwood, United StatesTaking people
- Lake CityLake City, United StatesTaking people
- LakelandLakeland, United StatesTaking people
- LaytonLayton, United StatesNot yet recruiting
- Little RockLittle Rock, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- Lutherville-TimoniumLutherville-Timonium, United StatesNot yet recruiting
- MaumeeMaumee, United StatesTaking people
- McKinneyMcKinney, United StatesNot yet recruiting
- MobileMobile, United StatesNot yet recruiting
- NashvilleNashville, United StatesTaking people
- Newport NewsNewport News, United StatesTaking people
- NormanNorman, United StatesNot yet recruiting
- OntarioOntario, United StatesNot yet recruiting
- Oxon HillOxon Hill, United StatesTaking people
- ParisParis, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesNot yet recruiting
- RaleighRaleigh, United StatesNot yet recruiting
- RedmondRedmond, United StatesNot yet recruiting
- RidgelandRidgeland, United StatesTaking people
- RosedaleRosedale, United StatesNot yet recruiting
- San AntonioSan Antonio, United StatesNot yet recruiting
- SheffieldSheffield, United StatesNot yet recruiting
- Sioux CitySioux City, United StatesNot yet recruiting
- SkokieSkokie, United StatesNot yet recruiting
- South JordanSouth Jordan, United StatesNo longer taking part
- Toms RiverToms River, United StatesNot yet recruiting
- TroyTroy, United StatesTaking people
- ViennaVienna, United StatesNot yet recruiting
- WebsterWebster, United StatesNo longer taking part
- ZacharyZachary, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662109EU 2025-523941-81-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication; HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.